Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery

Blood

Volumn 127, Issue 3, 2016, Pages 365-367

  Meroni, Pier Luigi ^a,b   Macor, Paolo ^c   Durigutto, Paolo ^c   De Maso, Luca ^c   Gerosa, Maria ^a   Ferraresso, Mariano ^a,d   Borghi, Maria Orietta ^a,b   Mollnes, Tom Eirik ^e,f,g   Tedesco, Francesco ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e NORDLAND HOSPITAL   (Norway)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C9; ECULIZUMAB; IMMUNOGLOBULIN G; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; WARFARIN; ANTIGEN ANTIBODY COMPLEX;

ADULT; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERIAL STENT; ARTERY SURGERY; BLOOD VESSEL OCCLUSION; BYPASS SURGERY; CASE REPORT; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; COMPLEMENT HEMOLYSIS TEST; DEEP VEIN THROMBOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOOT AMPUTATION; HUMAN; LEG ISCHEMIA; LUNG EMBOLISM; MIDDLE AGED; NONHUMAN; NOTE; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; SEIZURE; SKIN ULCER; ADVERSE EFFECTS; ANTIGEN ANTIBODY COMPLEX; BLOOD; COMPLICATION; FEMORAL ARTERY; IMMUNOLOGY; PATHOLOGY; THROMBECTOMY; THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIGEN-ANTIBODY COMPLEX; ANTIPHOSPHOLIPID SYNDROME; COMPLEMENT ACTIVATION; FEMALE; FEMORAL ARTERY; HUMANS; MIDDLE AGED; THROMBECTOMY; THROMBOSIS;

EID: 84958185001     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-09-672139     Document Type: Note

References (12)

1. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368(11):1033-1044.
2. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011;7(6):330-339.
3. Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood. 2005;106(7):2340-2346.
4. Agostinis C, Biffi S, Garrovo C, et al. In vivo distribution of b2 glycoprotein I under various pathophysiologic conditions. Blood. 2011;118(15):4231-4238.
5. Saunders KH, Erkan D, Lockshin MD. Perioperative management of antiphospholipid antibody-positive patients. Curr Rheumatol Rep. 2014;16(7): 426-434.
6. Agostinis C, Durigutto P, Sblattero D, et al. A non-complement-fixing antibody to b2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood. 2014;123(22):3478-3487.
7. Romay-Penabad Z, Carrera Marin AL, Willis R, et al. Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. Lupus. 2014;23(12):1324-1326.
8. Marzari R, Sblattero D, Macor P, et al. The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies. Eur J Immunol. 2002;32(10):2773-2782.
9. Noris M, Galbusera M, Gastoldi S, et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014;124(11):1715-1726.
10. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
11. Strakhan M, Hurtado-Sbordoni M, Galeas N, Bakirhan K, Alexis K, Elrafei T. 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: A case report and review of literature. Case Rep Hematol. 2014; 2014:704371.
12. Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies: Task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13(6):685-696.